Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCELOT: Osimertinib Rechallenge in EGFR-mutated NSCLC
NCT04335292Phase 2Recruiting
- Start
- Jan 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC). Started Jan 2021; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04335292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335292.